Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

SPRO – Spero Therapeutics, Inc.

Spero Therapeutics, Inc.
SPRO
$2.66
Name : Spero Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $148,520,912.00
EPSttm : -1.28
finviz dynamic chart for SPRO
Spero Therapeutics, Inc.
$2.66
3.84%
$0.0964

Float Short %

1.7

Margin Of Safety %

Put/Call OI Ratio

0.61

EPS Next Q Diff

EPS Last/This Y

0.43

EPS This/Next Y

0.84

Price

2.56

Target Price

5

Analyst Recom

3

Performance Q

224.87

Relative Volume

0.46

Beta

1.31

Ticker: SPRO




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07SPRO0.58030.050.00753
2025-05-08SPRO0.58160.040.00833
2025-05-09SPRO0.6290.040.00863
2025-05-12SPRO0.610.040.00907
2025-05-13SPRO0.68980.030.001360
2025-05-14SPRO0.67580.030.001365
2025-05-15SPRO0.6650.030.001385
2025-05-16SPRO0.66020.020.001468
2025-05-19SPRO0.68930.020.001571
2025-05-20SPRO0.680.020.001572
2025-05-21SPRO0.70390.020.001572
2025-05-22SPRO0.6810.020.001686
2025-05-23SPRO0.690.020.001736
2025-05-27SPRO0.69990.020.001744
2025-05-28SPRO2.360.020.221744
2025-05-29SPRO2.1850.160.696701
2025-05-30SPRO2.550.220.347727
2025-06-02SPRO2.720.270.3013694
2025-06-03SPRO2.650.315.9913843
2025-06-04SPRO2.660.610.4617046
2025-06-05SPRO2.570.611.8417364
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07SPRO0.58-129.2- -2.32
2025-05-08SPRO0.58-129.2- -2.32
2025-05-09SPRO0.62-129.2- -2.32
2025-05-12SPRO0.61-129.2- -2.32
2025-05-13SPRO0.69-129.2- -2.32
2025-05-14SPRO0.65-129.2- -2.32
2025-05-15SPRO0.66-129.2- -2.32
2025-05-16SPRO0.66-129.2- -2.32
2025-05-19SPRO0.69-72.7- -2.32
2025-05-20SPRO0.68-72.7- -2.32
2025-05-21SPRO0.69-72.7- -2.32
2025-05-22SPRO0.68-72.7- -2.32
2025-05-23SPRO0.69-72.7- -2.32
2025-05-27SPRO0.683.0- -0.84
2025-05-28SPRO2.313.0- -0.84
2025-05-29SPRO2.203.0- -0.84
2025-05-30SPRO2.503.0- -0.84
2025-06-02SPRO2.733.0- -0.84
2025-06-03SPRO2.643.0- -0.84
2025-06-04SPRO2.673.0- -0.84
2025-06-05SPRO2.563.0- -0.84
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07SPRO-1.838.642.13
2025-05-08SPRO-1.838.642.13
2025-05-09SPRO-1.838.642.13
2025-05-12SPRO-1.818.601.73
2025-05-13SPRO-1.608.601.73
2025-05-14SPRO-1.608.601.73
2025-05-15SPRO-1.608.601.73
2025-05-16SPRO-1.608.601.73
2025-05-19SPRO-1.604.481.73
2025-05-20SPRO-1.604.481.73
2025-05-21SPRO-1.604.481.73
2025-05-22SPRO-1.604.481.73
2025-05-23SPRO-1.604.481.73
2025-05-27SPRO-1.6043.791.73
2025-05-28SPRO-1.6043.791.70
2025-05-29SPRO-1.6043.791.70
2025-05-30SPRO-1.6043.791.70
2025-06-02SPRO-1.6040.771.70
2025-06-03SPRO-1.6040.771.70
2025-06-04SPRO-1.6040.771.70
2025-06-05SPRO-1.6040.771.70
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.25

Avg. EPS Est. Current Quarter

-0.32

Avg. EPS Est. Next Quarter

-0.25

Insider Transactions

-1.6

Institutional Transactions

40.77

Beta

1.31

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

15

Growth Score

33

Sentiment Score

93

Actual DrawDown %

89.2

Max Drawdown 5-Year %

-97.5

Target Price

5

P/E

Forward P/E

PEG

P/S

5.06

P/B

4.23

P/Free Cash Flow

EPS

-1.28

Average EPS Est. Cur. Y​

-0.84

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-246.49

Relative Volume

0.46

Return on Equity vs Sector %

-230.3

Return on Equity vs Industry %

-212.5

EPS 1 7Days Diff

0.7

EPS 1 30Days Diff

0.74

EBIT Estimation

Spero Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 32
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
stock quote shares SPRO – Spero Therapeutics, Inc. Stock Price stock today
news today SPRO – Spero Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SPRO – Spero Therapeutics, Inc. yahoo finance google finance
stock history SPRO – Spero Therapeutics, Inc. invest stock market
stock prices SPRO premarket after hours
ticker SPRO fair value insiders trading